Barclays starts coverage of Intuitive Surgical stock at Overweight

Published on 10/07/2026 at 16:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 2.89 billion, up from USD 2.44 billion. Intuitive Surgical stock costs EUR 365.88 on October 7, 2026 after EUR 360.63.

Extreme Makrofotografie einer miniaturisierten chirurgischen Roboterarmspitze mit Nadelhalter-Handgelenk, feinen Kabelzügen und präzisionsgefrästen Titangelenken, flache Schärfentiefe, metallisch-blaue Töne — Intuitive Surgical US46120E6023 Makroaufnahme zeigt miniaturisierten Roboter Endeffektor mit präziser feiner Gelenkmechanik, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) was trading at EUR 365.88 at Lang & Schwarz on October 7, 2026 at 3:42 p.m. CEST, up 1.46 percent versus the prior close of EUR 360.63. The latest analyst action came from Barclays, which initiated coverage at Overweight with a USD 485.00 price target on October 6, 2026, as reported by Aktiencheck.

Second-quarter revenue rose 18.44 percent

For the quarter ended June 30, 2026, revenue reached USD 2.89 billion, versus USD 2.44 billion in the year-earlier quarter. Net profit rose to USD 818.1 million from USD 658.4 million, increases of 18.44 percent and 24.27 percent respectively, according to Markets Insider.

The figures give Barclays a recent operating backdrop for its new rating. Revenue growth remained positive in the latest reported quarter, while the profit increase exceeded the revenue increase by 5.83 percentage points.

Barclays sets a USD 485.00 target

Barclays' USD 485.00 target stands 16.55 percent above the Nasdaq quote of USD 416.10 at 9:59 a.m. ET on October 7, 2026, based on the target and market price cited in the coverage report from Aktiencheck. Intuitive Surgical trades on Nasdaq under the ticker ISRG, according to Investing.com.

The target is not the only number shaping the outlook. A Q2 summary published by Investing.com said US procedure growth slowed to 12.00 percent from 14.00 percent in the first quarter, while full-year 2026 da Vinci procedure growth guidance remained at 13.50 percent to 15.50 percent. That gap between sustained companywide growth and slower US procedure expansion is the central counterweight to the bullish analyst stance.

Stock gains 1.46 percent in euros

Intuitive Surgical's market capitalization was USD 147.0 billion on October 7, 2026, while its 52-week Nasdaq range was USD 328.57 to USD 603.88. The euro quote therefore sits within a company picture that combines a large valuation with a substantial distance from the 52-week high.

At Lang & Schwarz, Intuitive Surgical stock was trading at EUR 365.88 on October 7, 2026 at 3:42 p.m. CEST, plus 1.46 percent versus the prior close of EUR 360.63 on October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.